• 1
    Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 2
    Kreiss H, Oberbauer R, Campistol J et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 3
    Benito A, Furlong T, Martin P et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 19241929.
  • 4
    Fortin MC, Raymond MA, Madore F et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4: 946952.
  • 5
    Paramesh A, Grosskreutz C, Florman S et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77: 129131.
  • 6
    Robson M, Coté I, Abbs I, Koffman G, Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324327.
  • 7
    Russ G, Campbell S, Chadban S et al. Reduced and standard target cencentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc 2003; 35: 115S117S.
  • 8
    Saikali J, Truong L, Suki W. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229230.
  • 9
    Reynolds J, Agoda L, Yuan C, Abbott K. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 10581068.
  • 10
    Langer R, Buren CV, Katz S, Khan B. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplant 2002; 73: 756760.
  • 11
    Barone G, Gurley B, Abul-Ezz S, Gokden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42: 20022006.
  • 12
    Crew R, Radhakrishnan J, Cohen D et al. De nono thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005; 20: 203209.
  • 13
    Hay N, Sonenberg N. Upstream and downstream of mTor. Genes Dev 2004; 18: 19261945.
  • 14
    Bjornsti M, Houghton P. The TOR pathway: a target for cancer therapy. Nat Rev 2004; 4: 335348.
  • 15
    Kirken R, Wang Y. Molecular actions of Sirolimus: sirolimus and mTor. Transplant Proc 2003; 35: 227S230S.
  • 16
    Koromilas A, Lazaris-Karatzas A, Sonenberg N. mRNAS containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing intiation factor eIF-4E. EMBO J 1992; 11: 5138.
  • 17
    Guba M, Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
  • 18
    Bruns C, Koehl G, Guba M et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004; 10: 21092119.
  • 19
    Brown L, Berse B, Tognazzi K et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 14571461.
  • 20
    Gröne HJ, Simon M, Gröne EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259267.
  • 21
    Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707.
  • 22
    Pilmore H, Eris J, Painter D, Bishop G, McCaughan G. Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 1999; 67: 929933.
  • 23
    Shihab FS, Bennett WM, Yi H, Andoh TF. Expression of vascular endothelial growth factor and its receptors FLT-1 and KDR/FLK-1 in chronic cyclosporine nephrotoxicity. Transplantation 2001; 72: 164167.
  • 24
    Kim Y, Suga S, Kang D et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000; 58: 23902399.
  • 25
    Shahbazi M, Fryer A, Pravica V et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260264.
  • 26
    Kang D, Joly A, Oh S et al. Impaired angiogenesis in the remnant kidney model: potentiel role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 14341447.
  • 27
    Kang D, Johnson R. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003; 12: 4349.
  • 28
    Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest 1986; 55: 455462.